4Popov NT, Stoyanova VK, Madzhirova NP,et al. Epigenetic aspects in schizophrenia etiology and pathogenesis [J]. Folia Med (Plovdiv), 2012,54(2) : 12-16.
5Sumiyoshi T, Matsui M, Nohara S, et al. Enhancement of cognitive per- formance in schizophrenia by addition of tandospirone to neuroleptic treatment [J]. Am J Psychiatry,2001,158(10) : 1722-1725.
6沈渔邨. 精神病学[M]. 第5 版. 北京:人民卫生出版社,2009:862.
7Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred yearsof schizophrenia: a meta -analysis of the outcome literature[J].Am J Psychiatry, 1994, 151(10):1409-1416.
8Kane JM, Marder SR. Schizophrenia: somatic treatment. In:Sadock BJ, Sadock VA eds. Kaplan ﹠ Sadock' s comprehensivetextbook of psychiatry[M]. New York,NY: Lippincott Williams﹠ Wilkins, 2005:1467-1476.
9Buckley NA, Sanders P. Cardiovascular adverse effects of antipsy-chotic drugs[J]. Drug Saf, 2000, 23(3):215.
10Cohen H, Loewenthal U, Matar M, et al. Association of auto-nomic dysfunction and clozapine:heart rate variability and risk forsudden death in patients with schizophrenia on long-term psycho-tropic medication[J]. Br J Psychiatry, 2001, 17(9):167-171.
